1. Scrip
  2. >>Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's podcast version of Five Must-Know Things, hear about whether safety concerns may affect JAK inhibitors, Takeda’s strategic R&D plans, Cigna’s psoriasis insurance program, Phase III readouts to look for, and an overview of the global pharma R&D pipeline.

Scrip Five Must Know Things
Weekly Audio Roundup Of Global Biopharma News

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 9 April 2021, including: safety concerns for JAK inhibitors; Takeda’s R&D...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Japan H1 Roundup: Pipeline Shifts Bring Mixed Results

 
• By Lisa Takagi

While Astellas and Daiichi Sankyo rang in double-digit growth, Eisai offset LOE impact with Leqembi’s performance. Takeda struggled with negative results but announced several growth initiatives.

Deal Watch: GSK To Tap AN2’s Boron Chemistry Approach In Tuberculosis R&D

 
• By Joseph Haas and Sushmita Panda

Also deals involving Lyell/Innovative Cellular, Lilly/Ailux, Dynavax/Vaxart, AVEO/HiberCell, Incyte/Prelude, AmacaThera/Pacira, Roche/Manifold and Chromatin/Purespring.

Jefferies Conference 2025: Five Themes To Follow

 
• By Andrew McConaghie

The investor event will bring deal-hungry big pharma and biotech execs together but input from the FDA’s unsettled leadership will be missing this year.

Bayer Boss Cautious On Late-Stage Deals Despite Beyonttra Success

 
• By Kevin Grogan

CEO Bill Anderson tells Scrip that the German group looks at potential in-licensing opportunities across every stage of the pipeline “but as you know, good value is a lot harder to come by in the late stage.”

More from Scrip

Bayer Boss Cautious On Late-Stage Deals Despite Beyonttra Success

 
• By Kevin Grogan

CEO Bill Anderson tells Scrip that the German group looks at potential in-licensing opportunities across every stage of the pipeline “but as you know, good value is a lot harder to come by in the late stage.”

Investors Shower Chinese In Vivo CAR-T Biotechs With Quick Cash

 
• By Dexter Jie Yan

Byterna, Starna, Vivacta and DeliNova ride surging investor sentiment on in vivo CAR-T assets to secure venture funding.

MASH Updates: Sagimet, Altimmune, GSK Discuss Development Plans At AASLD

 
• By Joseph Haas

Sagimet may shift focus to later-stage MASH while it lines up Phase III financing. Altimmune expects its dual agonist to show efficacy and tolerability, while GSK is readying efimosfermin as the third FGF21 analog into Phase III for MASH.